About: A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses
Creator	Ng, Lisa Chai, Christina Ching, Kuan-Chieh
Source	PMC
abstract	Alphaviruses were amongst the first arboviruses to be isolated, characterized and assigned a taxonomic status. They are globally widespread, infecting a large variety of terrestrial animals, birds, insects and even fish. Moreover, they are capable of surviving and circulating in both sylvatic and urban environments, causing considerable human morbidity and mortality. The re-emergence of Chikungunya virus (CHIKV) in almost every part of the world has caused alarm to many health agencies throughout the world. The mosquito vector for this virus, Aedes, is globally distributed in tropical and temperate regions and capable of thriving in both rural and urban landscapes, giving the opportunity for CHIKV to continue expanding into new geographical regions. Despite the importance of alphaviruses as human pathogens, there is currently no targeted antiviral treatment available for alphavirus infection. This mini-review discusses some of the major features in the replication cycle of alphaviruses, highlighting the key viral targets and host components that participate in alphavirus replication and the molecular functions that were used in drug design. Together with describing the importance of these targets, we review the various direct-acting and host-targeting inhibitors, specifically small molecules that have been discovered and developed as potential therapeutics as well as their reported in vitro and in vivo efficacies.
has issue date	2017-07-21(xsd:dateTime)
bibo:doi	10.1093/jac/dkx224
bibo:pmid	28981632
has license	no-cc
sha1sum (hex)	c597c98d0ff8bfaab9c264693a37d3892dd45093
schema:url	https://doi.org/10.1093/jac/dkx224
resource representing a document's title	A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses
has PubMed Central identifier	PMC7110243
has PubMed identifier	28981632
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:c597c98d0ff8bfaab9c264693a37d3892dd45093#body_text
is schema:about of	named entity 'DIRECT' named entity 'HOST' named entity 'INHIBITORS' named entity 'EQUAL' named entity 'AUTHORS' named entity 'ALPHAVIRUSES' named entity 'SMALL MOLECULE' named entity 'TARGETING' named entity 'THERAPIES' named entity 'CONTRIBUTION' named entity '80%' named entity 'ARTICLE' named entity 'COMPENDIUM' named entity 'small molecule' named entity 'RdRp' named entity 'arbidol' named entity 'arbidol' named entity 'endoplasmic reticulum' named entity 'ribavirin' named entity 'tetracycline antibiotic' named entity 'virus' named entity 'nucleocapsid' named entity 'binding affinity' named entity 'Venezuelan equine encephalitis virus' named entity 'inosine' named entity 'CHIKV' named entity 'VEEV' named entity 'viral particles' named entity 'CHIKV' named entity 'CHIKV' named entity 'furin' named entity 'geldanamycin' named entity 'homology' named entity 'berberine' named entity 'non-structural proteins' named entity 'protein' named entity 'host cell' named entity 'virions' named entity 'S-Adenosyl methionine' named entity 'IFN-a' named entity 'encephalitis' named entity 'indole' named entity 'RNA' named entity 'SFV' named entity 'viruses' named entity 'obatoclax' named entity 'alphavirus' named entity 'ivermectin' named entity 'ribavirin' named entity 'CHIKV' named entity 'antiviral' named entity 'virus' named entity 'Mycophenolic acid' named entity 'small molecules' named entity 'polyarthralgia' named entity 'antivirals' named entity 'dioxane' named entity 'VEEV' named entity 'CHIKV' named entity 'viral RNA' named entity 'imidazole' named entity 'binding affinities' named entity 'positive-sense RNA genome' named entity 'protein' named entity 'PHB' named entity 'SFV' named entity 'virion' named entity 'phenotypic' named entity 'arbidol' named entity 'African trypanosomiasis' named entity 'SAR' named entity 'suramin' named entity 'antiviral' named entity 'RNA' named entity 'RNA' named entity 'immunotherapy' named entity 'hydrophobic' named entity 'obatoclax' named entity 'RNA virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software